This webinar was recorded on Wednesday, 6th November 2024.

Join us for an in-depth exploration of the emerging applications and platforms in liquid biopsy. This session will highlight the most recent advancements in early cancer detection and targeted therapies, while also addressing critical challenges in patient access and reimbursement. Featuring thought leaders from across the industry, this webinar will provide valuable insights into the innovations shaping the future of liquid biopsy and its clinical impact.

‍

Speakers:

• Rehan Verjee, Chief Executive Officer at Precede Biosciences‍
• Dawn Mattoon, Chief Executive Officer at Mercy BioAnalytics, Inc.
• Peter Bach, Chief Medical Officer at DELFI Diagnostics
• Sarah Clancey Overton, Director of RCM at Velsera
• Mark Sausen, Executive Director, Head of Technology Innovation, PGDx, Labcorp

Moderators:

• Andrew Aijian, Ph.D., Partner at DeciBio Consulting
• Rishi Kayathi, Product Manager at DeciBio Consulting
• Juilee Malavade, Ph.D., Life Science Expert at DeciBio Consulting

‍

View the webinar recording and slides below:

‍

‍

Stay ahead of the curve in the rapidly evolving oncology diagnostics landscape with DeciBio's Oncology Diagnostics Market Intelligence Package. This bundle combines our industry-leading reports on two key segments: oncology liquid biopsy and clinical oncology biomarker testing.

Learn more about DeciBio's Oncology Diagnostics Market Intelligence Package here: https://www.decibio.com/product/oncology-diagnostics-market-intelligence-package

‍